Rating: HOLD
| Metric | Value |
|---|---|
| Current Price | $211 |
| Triangulated Fair Value | $197 |
| 12-mo Scenario PWEV | $212 |
| Implied Return | -6% |
| Forward P/E | 18.9x |
| Market Cap | $20B |
| 52-Week Range | $195 – $268 |
Methodology: Valuation triangulated across five independent anchors — Monte Carlo (Student-t + regime switching), an independent DCF, peer re-rating, a sum-of-parts, and a scenario-weighted PWEV. Figures reconciled to Alpha Vantage 2026-06-27. Each chart below sits with the part of the thesis it evidences.
Investment Thesis
The bull case — 'Bull — Re-Rate' (8% weight) — targets $375, +78% vs spot. It needs the multiple to hold or expand.
The dashboard below is the whole argument on one page: spot ($211) against each valuation anchor, the scenario tree, technicals and the options-implied move.
Anti-Thesis (The Real Bear Case)
The structural case — 'Structural — Reimbursement / Competition / GLP-1 Procedure Hit' (20%) — targets $93, -56% vs spot. This sits below the 52-week low — a genuine structural impairment, not a mild pullback.
Key Debate
P/E Multiple explains 60% of Monte Carlo outcome variance — i.e. value is set by the multiple the market will pay, a rate/sentiment regime bet as much as an earnings bet.
Earnings-Call Disconfirmation & Sentiment
Derived signals from the MCH market-data store (Alpha Vantage transcripts + news). Quantitative tone only — a disconfirmation flag, not a substitute for reading the call.
Management vs analyst tone (2026Q2): management +0.44 vs analyst floor +0.42 → delta +0.02 (n=16 mgmt / 11 Q&A; 1th pctile across the S&P book, z -2.3).
Flag: CANDID — management unusually candid/cautious vs peers (relatively low spin).
| Quarter | Mgmt | Analyst | Delta |
|---|---|---|---|
| 2026Q2 | +0.44 | +0.42 | +0.02 |
| 2026Q1 | +0.27 | +0.00 | +0.27 |
| 2025Q4 | +0.27 | +0.27 | +0.00 |
| 2025Q3 | +0.34 | +0.14 | +0.20 |
News (last 365d, 1000 articles): avg ticker sentiment +0.24 (bullish 32% / bearish 1%)
Scenario Analysis
The tree runs from a structural 'Structural — Reimbursement / Competition / GLP-1 Procedure Hit' downside ($93) to a 'Bull — Re-Rate' bull case ($375); the probability-weighted blend (PWEV $212) is +1% versus spot.
| Scenario | Probability | Target | Return |
|---|---|---|---|
| Structural — Reimbursement / Competition / GLP-1 Procedure Hit | 20% | $93 | -56% |
| Hospital-Capex / Utilization Recession | 17% | $158 | -25% |
| Base — Procedure Volume + Innovation | 35% | $220 | +4% |
| Growth — New-Product Cycle / Penetration | 20% | $297 | +41% |
| Bull — Re-Rate | 8% | $375 | +78% |
| Probability-Weighted (PWEV) | — | $212 | +1% |
Scenario rationale — what each probability buys (the driver path behind every target):
- Structural — Reimbursement / Competition / GLP-1 Procedure Hit (20%, $93). Structural impairment — reimbursement / competition / GLP-1 procedure hit: earnings AND the multiple compress together. Target sits below the 52-week low by construction. Drivers — implied_target: 93.13; probability: 0.2.
- Hospital-Capex / Utilization Recession (17%, $158). Cyclical downturn — procedure volumes + product-innovation cycle + hospital capital spending weakens for 1–2 years before normalising. Drivers — implied_target: 158.15; probability: 0.17.
- Base — Procedure Volume + Innovation (35%, $220). Mid-cycle — normalised procedure volumes + product-innovation cycle + hospital capital spending; disciplined capital allocation; steady returns. Drivers — implied_target: 219.66; probability: 0.35.
- Growth — New-Product Cycle / Penetration (20%, $297). Upside — new-product cycle + penetration lifts earnings above mid-cycle; the multiple expands modestly. Drivers — implied_target: 296.54; probability: 0.2.
- Bull — Re-Rate (8%, $375). Upside tail — sustained tight conditions or a structural re-rate on new-product cycle + penetration. Drivers — implied_target: 374.51; probability: 0.08.
Valuation Triangulation
Five anchors — but read them with their basis in mind. The Monte Carlo, the DCF terminal, and the peer re-rate all key off a market multiple, so they are not fully independent; only the discounted cash flows themselves are genuinely multiple-free. The discipline is to read the spread and weight the cash-based view, not to treat five numbers as five independent votes.
| Method | Basis | Fair Value | vs Spot |
|---|---|---|---|
| Monte Carlo median (Student-t + regime) | multiple | $190 | -10% |
| Peer P/E re-rate | multiple | $212 | +1% |
| Peer EV/Revenue re-rate | multiple | $270 | +28% |
| Scenario PWEV | multiple | $212 | +1% |
| DCF (5-year + terminal) | cash flow + terminal × | $186 | -12% |
| Triangulated (weighted) | — | $197 | -6% |
Monte Carlo — the distribution, not a point
10,000 paths, Student-t shocks (fat tails) with a regime-switching overlay. The median lands at $190 and 40% of paths finish above spot. The variance decomposition shows the p/e multiple is the dominant swing factor (60% of variance). Value is a multiple bet: fundamentals move the answer far less than the rating does.
DCF — the cash-flow anchor
Independent of the market multiple: a 5-year path, WACC 8.5%, 16x terminal FCF multiple → $186. This anchor is deliberately the heaviest (41%): it is the valuation least hostage to the current multiple regime.
Peer benchmarking — relative value
Against the peer cohort, re-rating to the peer-median forward multiple (P/E 19.03x) implies $212. A premium is only justified by superior growth/margins; otherwise it is multiple risk. Weighted just 12% so the market's mood does not drive the fair value.
Across all anchors the spread is tight (the methods corroborate one another).
Revenue-Segment Breakdown
The company-specific drivers behind the valuation — each segment carries its own growth, margin, multiple and capex intensity. (Tags: FACT reported · ESTIMATE from disclosures · INFERENCE judgment.)
| Segment | Revenue | Mix | Growth | Op margin | Multiple | Capex % | Tag |
|---|---|---|---|---|---|---|---|
| Medical Devices & Equipment | $5.9B | 100% | 6% | 20% | 19x | 5% | ESTIMATE |
Named Exposures
Demand & pricing cycle (FACT/ESTIMATE)
| Dimension | Assessment |
|---|---|
| driver | procedure volumes + product-innovation cycle + hospital capital spending |
| net_debt_or_cash_b | -1.65 |
Capital intensity & shareholder returns (ESTIMATE)
| Dimension | Assessment |
|---|---|
| capex_pct_revenue | 0.05 |
| div_yield | 0.0119 |
Structural risk vs optionality (INFERENCE)
| Dimension | Assessment |
|---|---|
| downside | reimbursement / competition / GLP-1 procedure hit |
| upside | new-product cycle + penetration |
Industry Context — Health Devices Tools
This name sits in the Health Devices Tools as a medical_devices. procedure volumes + product-innovation cycle + hospital capital spending Its scenarios are not guessed in isolation — they inherit a single, shared view of the cluster's driver cycle, so the names that depend on the same event are mutually consistent.
Value chain: TMO (life_science_tools) · ABT (medical_devices) · ISRG (medical_devices) · DHR (life_science_tools) · SYK (medical_devices) · MDT (medical_devices) · BSX (medical_devices) · EW (medical_devices) · IDXX (animal_health) · BDX (medical_devices) · A (life_science_tools) · WAT (life_science_tools) · ZTS (animal_health) · IQV (life_science_tools) · GEHC (medical_devices) · RMD (medical_devices) · DXCM (medical_devices) · VEEV (life_science_tools) · MTD (life_science_tools) · WST (medical_devices) · STE (medical_devices) · ZBH (medical_devices) · COO (medical_devices) · SOLV (medical_devices) · ALGN (medical_devices) · RVTY (medical_devices) · BAX (medical_devices) · PODD (medical_devices) · CRL (life_science_tools) · TECH (life_science_tools)
| Shared state | Capex path | House view | This name implies |
|---|---|---|---|
| Reimbursement / Funding / Utilization Reset | 37% | 37% | |
| Mid-Cycle — Procedure & R&D Demand | 35% | 35% | |
| Upside — Innovation / Recovery Re-Rate | 28% | 28% |
On the cluster's key downside — Reimbursement / Funding / Utilization Reset () — this name implies 37% vs the cluster house view of 37% (in line with the house). The cluster's full cross-stock reconciliation governs that the names which ride the same capex cycle assign it comparable odds.
Structure: Shared State — The health_devices_tools cycle is the shared macro driver. Driver — procedure volumes + biopharma R&D/bioprocessing demand + hospital capex Dispersion — Members differ by cyclicality (quality compounders vs deep cyclicals).
Model Appendix
DCF — line items
| Year | Revenue | Op income | − Capex | + D&A | FCF | PV(FCF) |
|---|---|---|---|---|---|---|
| FY+1 | $6B | $1B | $0B | $0B | $1B | $1B |
| FY+2 | $7B | $1B | $0B | $0B | $1B | $1B |
| FY+3 | $7B | $2B | $0B | $0B | $1B | $1B |
| FY+4 | $7B | $2B | $0B | $0B | $1B | $1B |
| FY+5 | $8B | $2B | $0B | $0B | $1B | $1B |
| Terminal | — | — | — | — | $1B × 16x | $15B |
FCF is bridged: NOPAT + D&A − Capex − ΔNWC (capex intensity 5% of revenue, weighted from the segments) — not a single conversion fudge.
WACC 8.5% · Σ PV(FCF) $5B + PV(terminal) $15B = EV $20B; + net cash → equity $18B ÷ diluted shares 0.10B = $186/share (exit-multiple terminal).
- Gordon (perpetuity-growth) terminal at 2.5% → $196/share — a genuinely non-multiple, cash-based cross-check; the exit-multiple and Gordon values bracket the terminal-value risk.
- Incremental ROIC on the forecast capex ≈ 17% vs WACC 8% → above WACC — the build is value-creative.
Peer set
| Peer | EV/Rev | Fwd P/E | Growth | Op margin |
|---|---|---|---|---|
| ABT | 4.191x | 17.01x | 6% | 14% |
| ISRG | 12.95x | 38.61x | 6% | 31% |
| SYK | 5.26x | 21.05x | 6% | 18% |
| MDT | 3.35x | 13.51x | 6% | 22% |
| Median | 4.7255x | 19.03x | — | — |
Peer-median fwd P/E → $212; EV/Rev → $270.
Weighted fair-value math
| Anchor | Value | Weight | Contribution |
|---|---|---|---|
| DCF | $186 | 41% | $77 |
| Scenario PWEV | $212 | 29% | $62 |
| Monte Carlo median | $190 | 18% | $34 |
| Peer P/E | $212 | 12% | $25 |
| Triangulated | — | 100% | $197 |
Sensitivity
DCF/share — WACC × terminal multiple
| WACC ＼ Term× | 11.2x | 13.6x | 16.0x | 18.4x | 20.8x |
|---|---|---|---|---|---|
| 6% | $154 | $179 | $204 | $229 | $254 |
| 8% | $147 | $171 | $194 | $218 | $242 |
| 8% | $140 | $163 | $186 | $209 | $231 |
| 10% | $134 | $156 | $178 | $199 | $221 |
| 10% | $128 | $149 | $170 | $191 | $212 |
DCF/share — revenue CAGR Δ × op-margin Δ
| CAGRΔ ＼ MgnΔ | -3.0pp | -1.5pp | +0.0pp | +1.5pp | +3.0pp |
|---|---|---|---|---|---|
| -3.0pp | $139 | $152 | $164 | $176 | $188 |
| -1.5pp | $148 | $162 | $175 | $188 | $201 |
| +0.0pp | $158 | $172 | $186 | $200 | $214 |
| +1.5pp | $168 | $183 | $198 | $213 | $227 |
| +3.0pp | $179 | $194 | $210 | $226 | $242 |
Tornado — DCF/share swing by driver (widest first)
| Driver | Low | High | Swing |
|---|---|---|---|
| Op margin ±3pp | $158 | $214 | $56 |
| Terminal × ±15% | $163 | $209 | $46 |
| Revenue CAGR ±3pp | $164 | $210 | $46 |
| WACC ±1pp | $178 | $194 | $17 |
| FCF conversion ±10% | $186 | $186 | $0 |
Company lever — SoP/share vs Medical Devices & Equipment multiple (AI re-rating) (base 19x)
| Multiple | 13.3x | 16.1x | 19.0x | 21.8x | 24.7x |
|---|---|---|---|---|---|
| SoP/share | $792 | $962 | $1,139 | $1,309 | $1,485 |
Load-Bearing Assumptions
DCF: WACC 8%, terminal multiple 16×, FY+5 revenue $8B. Triangulation leans 41% on DCF, 29% on PWEV.
Reasons the Thesis Could Fail (Falsifiable)
The valuation is multiple-dependent (60% of variance); a de-rating toward the DCF anchor ($186) implies -12%.
Fact / Inference / Speculation
- FACT: Spot $211; 52-week range $195–$268; engine rating HOLD; base-case target $212 (+1%).
- INFERENCE: Triangulated FV $197 (-6%). P/E Multiple explains 60% of Monte Carlo outcome variance — i.e. value is set by the multiple the market will pay, a rate/sentiment regime bet as much as an earnings bet.
- SPECULATION: At current prices the embedded bet is that the multiple holds or expands — P/E Multiple carries 60% of outcome variance.
Recommendation: HOLD
Balanced: triangulated fair value $197 (-6% vs spot); the outcome hinges on P/E Multiple. The debate is P/E Multiple (60% of variance) — fundamentally a multiple/regime call. SBC runs —M TTM (disclosed in the appendix).